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Abstract
Background—Alcohol consumption increases breast cancer risk, but its effect may be modified
by hormone therapy (HT) use, such that exposure to both may be synergistic. Because many
women stopped taking HT after mid-2002, it is important to quantify risks associated with alcohol
consumption in the context of HT cessation, as these risks may be more relevant to cancer
prevention efforts today.
Methods—Among 40,680 eligible postmenopausal California Teachers Study cohort
participants, 660 were diagnosed with invasive breast cancer before 2010. Multivariate Cox
proportional hazards regression models were used to estimate relative risks (RR) and 95%
confidence intervals (CI).
Results—Increased breast cancer risk associated with alcohol consumption was observed among
postmenopausal women who were current HT users (RR=1.60, 95% CI: 1.13–2.26 and RR=2.11,
95% CI: 1.41–3.15 for <20 and ≥20 g/d of alcohol), with risks being similar by HT preparation.
Alcohol did not increase risk among women who had stopped using HT within 3 years or 3–4
years before completing the follow-up questionnaire or in the more distant past. Results were
similar for ER+ and ER+PR+ tumors; while power was limited, no increase in risk was observed
for ER- tumors.
Conclusions—Following the cessation of HT use, alcohol consumption is not significantly
associated with breast cancer risk, although a non-significant increased risk was observed among
women who never used HT.
Impact—Our findings confirm that concurrent exposure to HT and alcohol has a substantial
adverse impact on breast cancer risk. However, after HT cessation, this risk is reduced.
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INTRODUCTION
In a recent meta-analysis of the association between alcohol consumption and breast cancer
risk, an international expert panel found convincing evidence that women who consume
greater amounts of alcohol are at increased risk of breast cancer (1). However, substantial
heterogeneity between studies was observed and the report did not specifically address the
joint effects of alcohol and menopausal hormone therapy (HT) use. Results from the
California Teachers Study (CTS) cohort (2) and some (3–7), but not all (8–10), previous
studies have suggested that alcohol may increase breast cancer risk only among women who
also used HT but not among those who did not. Only a few studies have distinguished never
and former HT users when examining modification of the alcohol-breast cancer association.
As with the effects of current HT use, results for former use are also mixed; some studies
report a non-significant increase in risk of about 20%–30% (4, 8), while others have found
no increase in risk (2, 7). On the other hand, a pooled analysis suggested a significant 9%
increase in risk per 10g/d of alcohol, a result similar to that seen among never and current
HT users (9). Understanding the joint association between alcohol consumption, HT use,
and breast cancer risk has increasingly important implications in light of the substantial
decline in HT use after mid-2002 when the findings from the Women’s Health Initiative
(WHI) reported adverse effects of some HT (11–13). In the CTS, the percent of
postmenopausal women using HT has fallen from 60% at baseline, in 1995–1996, to 20% in
our 10-year follow-up in 2005–2006 (14). Thus, we evaluate the timely question of whether
and when the cessation of HT use among CTS participants affects the association between
alcohol consumption and breast cancer risk.
MATERIALS AND METHODS
The CTS includes 133,479 women who were active or retired teachers or administrators
participating in the California State Teachers Retirement System in 1995–96 when the
cohort was established (15). In 2005–06, a 10-year follow-up (hereafter referred to simply as
follow-up) questionnaire was mailed to cohort members; this was the fourth questionnaire
completed by participants. Both the baseline and follow-up questionnaires covered a wide
variety of issues related to breast cancer risk and women’s health, including alcohol
consumption and hormone therapy use.
The CTS study has been approved by the Institutional Review Boards of the Cancer
Prevention Institute of California, the State of California, the University of California,
Irvine, the University of Southern California, and the City of Hope.
Assessment of Alcohol Consumption
On the follow-up questionnaire women were asked how often they drank beer, white wine or
champagne, red wine, and cocktails or liquor. Response categories ranged from never to 5 or
more servings per day. They were also asked how much they consumed in each serving
based on photos of different size glasses ranging in volume from 5 to 16 ounces for wine
and cocktails and from 8 to 48 ounces for beer. For beer, portion size could also be reported
as the number of cans per serving, ranging from ½ to 4. Grams of alcohol per fluid ounce of
beverage were assigned as 1.1 for beer, 3.17 for wine, and 10.0 for liquor. When calculating
alcohol intake from liquor and cocktails, we assigned each drink 1 shot of alcohol (1.5
ounces) regardless of the portion size reported assuming that a larger portion size indicated
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more non-alcoholic components. Daily intake of grams of alcohol was calculated for each
woman. In analyses we used the following categories of exposure based on our previous
findings for the association between alcohol and breast cancer risk (2): non-drinkers (during
the past year), drinkers consuming <20 grams of total alcohol per day, and drinkers
consuming ≥20 g/d; the latter category being equivalent to approximately two or more
drinks per day.
Assessment of Hormone Therapy Use
On the follow-up questionnaire women were asked whether they had used HT (any type) in
the last five years and if so, the total months of HT use during that time period (with
response categories: 1–6, 7–12, 13–24, 25–36, 37–48, or 49–60 months). They were also
asked if they had used HT in the past month. HT use was also assessed on the 5-year follow-
up questionnaire and the baseline questionnaire. HT use at these three time points was used
to define five subgroups of women with different HT use patterns defined in relation to
status at the time the 10-year follow-up questionnaire was completed: currently using HT at
follow-up, stopped HT use in the past three years, stopped HT use 3–4 years ago, stopped
HT use more than 5 years ago, or never used HT.
Follow-up for Events
The CTS cohort is followed for cancer diagnoses, death, and changes of address. Annual
linkage between the California Cancer Registry (CCR) and the cohort membership is used to
identify incident cancer cases. The CCR is a population-based cancer registry that is
anchored in legislation that mandates reporting. It covers the entire state of California, has
interstate agreements with 13 other states for case-sharing purposes, is estimated to be over
99% complete (16), and is part of the National Cancer Institute’s Surveillance,
Epidemiology, and End Results (SEER) program. Thus, follow-up for cancer outcomes is
virtually complete as long as the cohort members reside in California. ER and PR results
were obtained from the CCR; a previous expert review, conducted for breast cancers
diagnosed as part of the SEER programs in Los Angeles and Detroit, found high
concordance with hormone receptor classification from registry data, which is obtained from
the individual hospital pathologists (17).
California and national mortality files are used to ascertain date and cause of death. Changes
of address are obtained by annual mailings, responses from participants, and routine record
linkages with multiple sources, including the US Postal Service National Change of Address
database.
Study population
For purposes of the present analyses, we excluded women who at baseline: were not residing
in California (n=8,867), had never had menstrual periods (n=62), or had a prior (n=6,215) or
an unknown (n=135) history of breast cancer; and who prior to the 10-year follow-up
questionnaire being mailed (for non-responders) or completed (for responders): had died
(n=8,644), refused further participation in the CTS (n=924), permanently (for more than 4
months) moved out of California (n=8,362), were age 85 years or older (n=5,131), or had
developed breast cancer (n=3,941). Among the remaining 91,198 cohort participants, 61,537
(67%) completed the follow-up questionnaire. From these women, we further excluded
those who returned the questionnaire in 2008 (n=16), who did not complete or incorrectly
completed the alcohol section of the follow-up questionnaire (n=2,100), or who completed
the short-form which did not include questions on alcohol consumption (n=6,617), or who
were not postmenopausal at the time of completing the follow-up questionnaire (n=12,124).
Among the 40,680 women eligible for this analysis, 660 were diagnosed with invasive
breast cancer after completing the follow-up questionnaire and before January 1, 2010. Of
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these 660 women, 530 (80%) had estrogen receptor positive (ER+) tumors, 94 (14%) had
ER negative (ER-) tumors, and 36 (5%) were missing information on ER status.
Progesterone receptor (PR) data were available for 92% of these 660 women.
Data Analysis
Follow-up time was calculated as the number of days from the date the follow-up
questionnaire was completed until the first of the following possible outcomes: date of
invasive breast cancer diagnosis, date of in-situ breast cancer diagnosis, date of death, date
the woman moved out of California (for at least four months), or December 31, 2009.
Women diagnosed with in-situ breast cancer (n=198) contributed person-days to the analysis
only up to the date of diagnosis, at which time they were censored from the analysis. For
analyses by tumor subtype, women whose ER status was unknown were excluded from the
analyses.
Relative risks (RR; hazard rate ratios) and 95% confidence intervals (CI) were estimated
using Cox regression models with age (in days) used as the time-scale and stratification by
age (in years) at follow-up. Relative risks were adjusted for the following potential
confounders: age at first full-term pregnancy (nulliparous, age <25 years, age ≥25 years,
missing), a family history of breast cancer in a first degree relative (yes, no, missing/
adopted), body mass index (kg/m2;; <25, 25–29.9, ≥30, missing), and average long-term
(from high school through age 54 years) physical inactivity (hours per week of moderate
activity; <1 (inactive), ≥1, missing). All covariates were assessed at baseline except body
mass index, which, along with updated alcohol consumption and HT use, were assessed at
follow-up. Effect modification under a multiplicative model was formally assessed by
computing likelihood ratio tests based on cross-product terms in the Cox regression models.
RESULTS
Table 1 presents the characteristics of the women included in the current analysis. In
addition, to assess how representative these women were of the cohort, we compared these
women to those meeting similar eligibility criteria but who not included in the current
analysis, i.e., postmenopausal women completing the short-version of the follow-up
questionnaire and women who did not respond to the follow-up questionnaire but were age
50 years or older at the time it was mailed (as a proxy indicator of postmenopausal status).
Both groups of women were similar on the factors included in this analysis as well as
alcohol consumption at baseline.
The impact of HT use on breast cancer risk in this sub-cohort was similar to that observed in
the total cohort (18): compared to never HT users, past users were not at increased risk
(RR=1.06, 95% CI: 0.85–1.33), while current users were (RR=1.63, 95% CI: 1.29–2.06).
Among past users, risk did not vary substantially by time since last use (defined as <3, 3–4,
or ≥5 years). Among current users, risk associated with ET use (RR=1.43, 95% CI: 1.09–
1.88) was statistically significant but lower than that associated with EPT use (RR=2.11,
95% CI: 1.53–2.91).
Alcohol consumption of <20 g/d at follow-up was not associated with breast cancer risk
overall or when stratified by time since HT cessation; with the exception of an increase in
risk among current HT users (RR=1.60, 95% CI: 1.13–2.26). While alcohol consumption of
≥20 g/d was associated with an overall increased risk of breast cancer (RR=1.26, 95% CI:
1.02–1.56; Table 2), this risk was limited to women who were current HT users (RR=2.11,
95% CI: 1.41–315 compared to non-drinkers who never used HT) with a statistically non-
significant elevation observed among women who never used HT (RR=1.52, 95% CI: 0.94–
2.47). Women who had stopped using HT before follow-up were not at increased risk even
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when consuming ≥20 g/d of alcohol, regardless of whether they had stopped taking HT
recently (within three and 3–4 years prior to follow-up) or in the more distant past. The
interaction between alcohol consumption and HT use, however, was not statistically
significant (pinteraction=0.38). When splitting women who were non-drinkers at follow-up
into never drinkers and former drinkers, the results were very similar (data not shown).
Since some previous studies have shown that the effects of alcohol are stronger for ER+ and
ER+PR+ breast tumors (6, 7), we examined the joint effects of alcohol and HT use and
cessation for specific hormone receptor subtypes. Table 3 presents the results for ER+
tumors and divides current HT users into those who used estrogen-only (ET) in the previous
five years and those who used combination estrogen-progesterone (EPT); women reporting
current HT use but with missing data on HT type (2%), who used progestin-only (<1%), or
who indicated using both ET and EPT during the previous five years (18%) were excluded
from this analysis. Compared to women who never used HT and did not consume alcohol,
those who consumed 20 or more g/d of alcohol and were current HT users were at
significantly increased risk of ER+ breast cancer (RR=2.03, 95% CI: 1.16–3.55 and
RR=4.09, 95% CI: 2.29–7.30 for ET and EPT users, respectively); however, no increase in
risk was observed for alcohol consumption of ≥20 g/d among those who had ceased using
HT (RR=1.20, 95% CI: 0.78–1.84; pinteraction=0.40). Given the breast cancer risk associated
with HT use alone (RR=1.05, 95% CI: 0.61–1.79 and RR=1.91, 95% CI: 1.01–3.59 for ET
and EPT use, respectively, among non-drinkers), the effects associated with the addition of
≥20 g/d of alcohol are similar, and approximately two-fold in magnitude, for ET and EPT
users. Alcohol consumption of ≥20 g/d among never HT users was slightly lower (RR=1.61,
95% CI: 0.93–2.77). Results were similar for ER+PR+ breast cancer (n=421; data not
shown). Statistical power was limited for examining risk for ER- breast cancer; however, no
increase in risk was observed (RR=0.65, 95% CI: 0.17–2.45 for alcohol of ≥20 g/d among
current HT users compared to non-drinkers who never used HT).
DISCUSSION
We found that alcohol consumption significantly increased the risk of breast cancer among
women who were concurrently using HT. Regardless of the type of HT used, HT plus
alcohol consumption of ≥20 g/d was associated with an approximately 2-fold increase in risk
over HT use alone. Former HT users, including women who stopped taking HT less than
three years before the follow-up questionnaire, who consumed ≥20 g/d of alcohol were not
at increased risk for breast cancer. However, a non-significant increase in risk with this level
of alcohol consumption was observed among never HT users. While statistical power to
detect differences by tumor type was limited, the effects for ER+ and ER+PR+ tumors were
similar to those observed overall and no indication of increased risk for ER- tumors was
seen.
Though not all studies (including two large pooling projects) have observed different effects
of alcohol on breast cancer risk according to HT use (9, 10, 19), a number of studies,
including more recently published results, have found some indication that differences may
exist (2, 4, 5, 7, 8, 20). Only a few studies have examined the effects of alcohol among past
HT users (2, 4, 7, 8). In our previous analysis of the CTS cohort, we observed no increased
risk associated with alcohol use among former users of estrogen-only therapy (ET) but
observed a significant increased risk among current ET users (2). Similar null associations
among former HT (type not specified) users were observed in the National Institutes of
Health-American Association for Retired Persons (NIH-AARP) Study, the Nurses’ Health
Study, and the Women’s Health Study cohorts (4, 7, 8). However, we believe that this is the
first study to examine the effects of alcohol intake by specific gradients of time since HT
cessation rather than combining all “former” users into a single group. The mass cessation of
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HT use following the publication of the WHI findings in mid-2002 provided a natural
experiment upon which ongoing cohort studies could capitalize. In the CTS, approximately
60% of postmenopausal participants were HT users at baseline but about two-thirds of these
women had stopped taking HT by the time of the 2005–2006 follow-up questionnaire. Our
findings suggest that the increased risk associated with the consumption of ≥20 g/d of
alcohol diminishes within the first three years following HT cessation. Unfortunately, the
small number of cases diagnosed within the first three years following HT cessation does
not allow us to determine more precisely how quickly the risk associated with alcohol
consumption disappears.
Unlike the results of the WHI randomized trial (21), ET is associated with increased breast
cancer risk in the CTS (18), as well as several other studies (22–24), albeit to a lesser extent
than EPT use. Reasons for this difference may be related to population differences in prior
hysterectomy (i.e., the WHI prescribed ET only to women with a hysterectomy while, in the
CTS about 20% of ET users had not had a hysterectomy (18)) or prior patterns of HT use
(25). Further, in the CTS, risks associated with both ET use and alcohol consumption are
greater among women with lower body mass index (BMI) (2, 18) and, the effects of ET use
on breast cancer risk increased with duration of use (18). On average, the CTS participants
have lower overall BMI and longer duration of ET use than other populations (15, 18). Thus,
the distribution of these lifestyle factors may contribute to the overall association we
observed between alcohol consumption, ET use, and breast cancer risk. Previous studies
addressing the alcohol-breast cancer relationship have not examined effects specific to HT
preparation (4, 7, 8).
Alcohol likely affects breast cancer risk, at least in part, through its influence on steroid
hormones. Consistent with our findings, a number of studies, including two meta-analyses,
have shown that alcohol increases the risk of ER+ and ER+PR+, but not ER- or triple
negative, breast cancers (6, 7, 26, 27). Alcohol has been shown to increase ER expression
and ER-α activity in vitro (28). It has also been associated with increased production and
reduced metabolism and clearance of estradiol and other steroid hormones, and with the
stimulation of P450-mediated conversion of pro-carcinogens and the inhibition of phase II
detoxification of carcinogens and DNA repair (28–31). In the absence of HT, alcohol may
result in a modest increase in serum estrogens or androgens (28). However, Ginsburg et al.
(30) found that estradiol levels among HT users who drank alcohol were three times higher
than those who did not drink alcohol, suggesting that the modest impact of alcohol on
estradiol levels may have a greater impact when combined with HT due to other metabolic
alterations (28). Consistent with this latter supposition, our findings suggest a minimal
impact of alcohol in the absence of concurrent HT use but a substantial alteration in risk
when alcohol and HT are combined. However, the statistically non-significant, elevation in
risk associated with alcohol consumption of ≥20 g/d among women who never used HT
suggests that this may be a heterogeneous group which includes women who are particularly
susceptible to the adverse effects of alcohol. Further mechanistic research, evaluation of
gene-alcohol interactions and breast cancer risk among women who have not used HT, and
additional investigation of the temporal impact of mass HT cessation in other cohorts or
pooled cohort data, particularly for finer subdivisions of the period within five years of
cessation, will help elucidate these relationships.
The major strengths of this analysis include the high reliability and validity of alcohol
measurements within the cohort (32) and the ability of cohort studies to capture ongoing
changes in population exposures while minimizing recall biases. Potential limitations
include non-response to the 10-year follow-up questionnaire, exposure misclassification,
limited statistical power for some analyses, and lack of generalizability to very high levels of
alcohol consumption. While response to the detailed 10-year follow-up questionnaire was
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only 67%, as seen in Table 1, the sub-cohort evaluated here was similar to the comparable
sub-cohort who did not complete the full 10-year follow-up questionnaire, suggesting
minimal bias from non-response. Misclassification of exposure is always of concern when
assessing dietary factors using a food-frequency questionnaire (FFQ) approach. However,
the reproducibility and validity of alcohol intake in our cohort is quite high: r=0.87 for
reproducibility and r~0.75 for alcohol compared to 24-hour recalls for our baseline
assessment (32). Stability of alcohol intake between our baseline and 10-year follow-up
questionnaire was moderate [r=0.50 for absolute consumption (g/d), 69% absolute
agreement for categories of intake (never, <20, and ≥20 g/d) with equal numbers of women
reducing and increasing their intake, and kappa=0.47]. The follow-up questionnaire asked
about the number of months that HT had been used in the last five years and provided
response categories that included several years. We used the median number of years in each
category to calculate when HT use ceased, thus, some misclassification of the time since
cessation may have occurred. In addition, we had a limited number of breast cancer cases
subsequently diagnosed among women who ceased using HT during the period <3 year
before completing the follow-up questionnaire, thus, it was not possible to adequately
evaluate risk for finer gradations of time since HT cessation. Thus, it remains unclear
whether the greater risk of breast cancer associated with alcohol consumption of ≥20 g/d
persists for some short time following HT cessation or diminishes very quickly. Therefore,
in terms of public health recommendations, we would conservatively suggest that alcohol
consumption remain limited to one drink per day for up to several years following HT
cessation, until more data for this early period is obtained. The group of women who
consumed ≥20 g/d of alcohol included primarily moderate drinkers, with only 5% of the
cohort consuming the equivalent of four or more drinks per day. Thus, our conclusions
should be interpreted in this context and not assumed to apply to greater amounts of alcohol
consumption.
In summary, we observed that among current HT users, alcohol consumption substantially
increased risk of ER+ tumors, the most common type of breast cancer. Among women who
had ceased using HT, risk associated with two or more alcoholic drinks per day was not
apparent; although a non-significant increased risk was observed among women who never
used HT. Thus, our findings confirm that concurrent exposure to HT and alcohol has a
substantial adverse impact on breast cancer risk. However, after HT cessation, the risk
associated with moderate alcohol consumption is reduced.
Acknowledgments
The authors would like to thank the CTS Steering Committee who is responsible for the formation and maintenance
of the cohort within which this study was conducted but who did not directly contribute to the current paper: Hoda
Anton-Culver, Ellen T. Chang, Dennis Deapen, Katherine D. Henderson, Huiyan Ma, David O. Nelson, Fredrick
Schumacher, Sophia S. Wang, and Argyrios Ziogas.
GRANT SUPPORT
This research was supported by grant R01 CA77398 from the National Cancer Institute and contract 97-10500 from
the California Breast Cancer Research Fund. The funding sources did not contribute to the design or conduct of the
study, nor to the writing or submission of this manuscript. The collection of cancer incidence data used in this study
was supported by the California Department of Public Health as part of the statewide cancer reporting program
mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance,
Epidemiology and End Results Program under contract HHSN261201000036C awarded to the Cancer Prevention
Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and
contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and
Prevention’s National Program of Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public
Health Institute. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of
California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and
Prevention or their Contractors and Subcontractors is not intended nor should be inferred.
Horn-Ross et al. Page 7














1. World Cancer Research Fund / American Institute for Cancer Research. Food, Nutrition, Physical
Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR; 2007.
2. Horn-Ross PL, Canchola AJ, West DW, Stewart SL, Bernstein L, Deapen D, et al. Patterns of
alcohol consumption and breast cancer risk in the California Teachers Study cohort. Cancer
Epidemiol Biomarkers Prev. 2004; 13:405–11. [PubMed: 15006916]
3. Gapstur SM, Potter JD, Sellers TA, Folsom AR. Increased risk of breast cancer with alcohol
consumption in postmenopausal women. Am J Epidemiol. 1992; 136:1221–31. [PubMed: 1476144]
4. Lew JQ, Freedman ND, Leitzmann MF, Brinton LA, Hoover RN, Hollenbeck AR, et al. Alcohol
and risk of breast cancer by histologic type and hormone receptor status in postmenopausal women:
the NIH-AARP Diet and Health Study. Am J Epidemiol. 2009; 170:308–17. [PubMed: 19541857]
5. Nielsen NR, Gronbaek M. Interactions between intakes of alcohol and postmenopausal hormones on
the risk of breast cancer. Int J Cancer. 2008; 122:1109–13. [PubMed: 17966122]
6. Suzuki R, Orsini N, Mignone L, Saji S, Wolk A. Alcohol intake and risk of breast cancer defined by
estrogen and progesterone receptor status - a meta-analysis of epidemiological studies. Int J Cancer.
2008; 122:1832–41. [PubMed: 18067133]
7. Zhang SM, Lee I-M, Manson JE, Cook NR, Willett WC, Buring JE. Alcohol consumption and
breast cancer risk in the Women’s Health Study. Am J Epidemiol. 2007; 165:667–76. [PubMed:
17204515]
8. Chen WY, Colditz GA, Rosner B, Hankinson SE, Hunter DJ, Manson JE, et al. Use of
postmenopausal hormones, alcohol, and risk for invasive breast cancer. Ann Intern Med. 2002;
137:798–804. [PubMed: 12435216]
9. Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA, et al.
Alcohol and breast cancer in women: a pooled analysis of cohort studies. J Am Med Assoc. 1998;
279:535–40.
10. Tjonneland A, Thomsen BL, Stripp C, Christensen J, Overvad K, Mellemkaer L, et al. Alcohol
intake, drinking patterns and risk of postmenopausal breast cancer in Denmark: a prospective
cohort study. Cancer Causes Control. 2003; 14:277–84. [PubMed: 12814207]
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks
and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From
the Women’s Health Initiative randomized controlled trial. J Am Med Assoc. 2002; 288:321–33.
12. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual
trends and response to recent evidence. J Am Med Assoc. 2004; 291:47–53.
13. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in
California from 2001 to 2004. J Clin Oncol. 2007; 25:3437–9. [PubMed: 17592152]
14. Marshall SF, Clarke CA, Deapen D, Henderson KD, Largent J, Neuhausen SL, et al. Recent breast
cancer incidence trends according to hormone therapy use: the California Teachers Study. Breast
Cancer Res. 2010; 12:R4. [PubMed: 20064209]
15. Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Reynolds P, et al. High breast
cancer rates among California teachers: Results from the California Teachers Study Cohort.
Cancer Causes Control. 2002; 13:625–35. [PubMed: 12296510]
16. Kwong, SL.; Perkins, CI.; Morris, CR.; Cohen, R.; Allen, M.; Schlag, R., et al. Cancer in
California: 1988–1998. Sacramento, CA: California Department of Health Services, Cancer
Surveillance Section; Dec. 2000
17. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon MS, et al. Breast cancer receptor
status: do results from a centralized pathology laboratory agree with SEER registry reports?
Cancer Epidemiol Biomarkers Prev. 2009; 18:2214–20. [PubMed: 19661080]
18. Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, et al. Menopausal hormone
therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers
Study. Cancer Epidemiol Biomarkers Prev. 2010; 19:2366–78. [PubMed: 20699377]
19. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr, et al. Alcohol, tobacco and
breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies,
Horn-Ross et al. Page 8













including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer.
2002; 87:1234–45. [PubMed: 12439712]
20. Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and postmenopausal
breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.
J Natl Cancer Inst. 2005; 97:1601–8. [PubMed: 16264180]
21. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of
conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health
Initiative randomized controlled trial. J Am Med Assoc. 2004; 291:1701–12.
22. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone
replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705
women with breast cancer and 108,411 women without breast cancer. Lancet. 1997; 350:1042–3.
[PubMed: 10213541]
23. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and
estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc. 2000; 283:485–
91.
24. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, et al.
Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol
Biomarkers Prev. 2002; 11:593–600. [PubMed: 12101105]
25. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, et al.
Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative Clinical Trial
and Observational Study. Am J Epidemiol. 2008; 167:1407–15. [PubMed: 18448442]
26. Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, Wactawski-Wende J, et al. Smoking and
alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of
postmenopausal women. Cancer Causes Control. 2011; 22:775–83. [PubMed: 21360045]
27. Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, et al. Alcohol consumption and
risk of postmenopausal breast cancer by subtype: the Women’s Health Initiative Observational
Study. J Natl Cancer Inst. 2010; 102:1–10.
28. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental
evidence and potential mechanisms. JAMA. 2001; 286:2143–51. [PubMed: 11694156]
29. Dorgan JF, Baer DJ, Albert PS, Judd JT, Brown ED, Corle DK, et al. Serum hormones and the
alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst. 2001; 93:710–5.
[PubMed: 11333294]
30. Ginsburg ES, Mello NK, Mendelson JH, Barbieri RL, Teoh SK, Rothman M, et al. Effects of
alcohol ingestion on estrogens in postmenopausal women. J Am Med Assoc. 1996; 276:1747–51.
31. Gavaler JS, Rosenblum E. Exposure-dependent effects of ethanol on serum estradiol and uterus
mass in sexually mature oophorectomized rats: a model for bilaterally ovariectomized-
postmenopausal women. J Stud Alcohol. 1987; 48:295–303. [PubMed: 3613579]
32. Horn-Ross PL, Lee VS, Collins CN, Stewart SL, Canchola AJ, Lee MM, et al. Dietary assessment
in the California Teachers Study: reproducibility and validity. Cancer Causes Control. 2008;
19:595–603. [PubMed: 18256894]
Horn-Ross et al. Page 9

























Horn-Ross et al. Page 10
Table 1
Selected characteristics of the cohort included in the present analysis and women meeting similar eligibilty
criteria but who did not complete the full 10-year follow-up questionnaire.
Follow-up cohort Non-participants
N % N %
N 40,680 100% 25,165 100%
At baseline
Age at first full-term pregnancy ( yrs)
 <25 yrs 12,446 31% 7,311 29%
 25–29 12,381 30% 7,453 30%
 ≥30 6,598 16% 4,377 17%
 nulliparous 8,640 21% 5,544 22%
 missing 615 2% 480 2%
Family history of breast cancer (1st degree relative)
 yes 5,203 13% 3,022 12%
 no 34,372 84% 21,069 84%
 missing/adopted 1,105 3% 1,074 4%
Average long-term physical activity (hrs/wk)
 <1 (inactive) 13,099 32% 8,755 35%
 ≥1 27,382 67% 16,208 64%
 missing 199 1% 202 1%
Alcohol consumption (g/d)
 none 12,157 30% 7,980 32%
 <20 23,685 58% 13,950 55%
 ≥20 3,457 9% 1,919 8%
 missing 1,381 3% 1.316 5%
At 10-year follow-up
Age (yrs)
 ≤54 3,467 9%
 55–64 18,040 44%
 65–74 11,676 29%
 75–84 7,497 18%
Body mass index (kg/m2)
 <25 20,379 50%
 25–29 12,369 30%
 ≥30 7,516 18%
 missing 416 1%
HT use
 current 9,249 23%
 stopped <5 yrs prior 10,112 25%
 stopped ≥5 yrs prior 10,788 27%
 never 9,342 23%
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Follow-up cohort Non-participants
N % N %
 missing 1,189 3%
Alcohol consumption (g/d)
 none 14,894 37%
 <20 18,896 46%
 ≥20 6,890 17%
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